BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance

被引：0
|
作者：
W T Parker
A L Yeoman
B A Jamison
D T Yeung
H S Scott
T P Hughes
S Branford
机构：
[1] Centre for Cancer Biology,Department of Molecular Pathology
[2] SA Pathology,Department of Haematology
[3] School of Medicine,undefined
[4] University of Adelaide,undefined
[5] School of Molecular and Biomedical Science,undefined
[6] University of Adelaide,undefined
[7] Centre for Cancer Biology,undefined
[8] SA Pathology,undefined
来源：
British Journal of Cancer | 2013年 / 109卷
关键词：
chronic myeloid leukaemia; mutation analysis; tyrosine kinase inhibitor; resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1593 / 1598
页数：5
相关论文
共 50 条
  • [1] BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
    Parker, W. T.
    Yeoman, A. L.
    Jamison, B. A.
    Yeung, D. T.
    Scott, H. S.
    Hughes, T. P.
    Branford, S.
    BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1593 - 1598
  • [2] BCR-ABL1 kinase domain mutations: Methodology and clinical evaluation
    Alikian, Mary
    Gerrard, Gareth
    Subramanian, Papagudi G.
    Mudge, Katherine
    Foskett, Pierre
    Khorashad, Jamshid Sorouri
    Lim, Ai Chiin
    Marin, David
    Milojkovic, Dragana
    Reid, Alistair
    Rezvani, Katy
    Goldman, John
    Apperley, Jane
    Foroni, Letizia
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (03) : 298 - 304
  • [3] A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia
    Lim, Ye Seul
    Jeong, Na-Rae
    Yoo, Sun-Mi
    Kim, Han Wool
    Lee, Song Hee
    Kim, Dong-Wook
    BLOOD, 2023, 142
  • [4] Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations
    Filip Razga
    Tomas Jurcek
    Daniela Zackova
    Dana Dvorakova
    Martina Toskova
    Ivana Jeziskova
    Jiri Mayer
    Zdenek Racil
    Molecular Diagnosis & Therapy, 2012, 16 : 251 - 259
  • [5] IMPACT OF TREATMENT ADMINISTRATION ON SELECTION OF BCR-ABL1 KINASE DOMAIN MUTATIONS
    Razga, F.
    Jurcek, T.
    Zackova, D.
    Dvorakova, D.
    Toskova, M.
    Jeziskova, I.
    Mayer, J.
    Racil, Z.
    HAEMATOLOGICA, 2012, 97 : 536 - 537
  • [6] Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations
    Razga, Filip
    Jurcek, Tomas
    Zackova, Daniela
    Dvorakova, Dana
    Toskova, Martina
    Jeziskova, Ivana
    Mayer, Jiri
    Racil, Zdenek
    MOLECULAR DIAGNOSIS & THERAPY, 2012, 16 (04) : 251 - 259
  • [7] Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
    Soverini, Simona
    de Benedittis, Caterina
    Mancini, Manuela
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S120 - S128
  • [8] Detection of ABL1 kinase Domain Mutations in Therapy Naive BCR-ABL1 Positive ALL
    Baer, Constance Regina
    Meggendorfer, Manja
    Haferlach, Claudia
    Kern, Wolfgang
    Haferlach, Torsten
    BLOOD, 2017, 130
  • [9] Detection and Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing
    Vannuffel, Pascal
    Cauwelier, Barbara
    De Rop, Celine
    Nollet, Friedel
    BLOOD, 2015, 126 (23)
  • [10] Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia
    Langabeer, Stephen E.
    McCarron, Sarah L.
    Haslam, Karl
    Preston, Lisa
    CLINICAL LABORATORY, 2016, 62 (05) : 975 - 976
12345